Ad40 Viral Vector E1 Deletion for Mucosal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adenovirus-based vectors require specific cell lines for efficient large-scale replication, limiting their application in treating gastrointestinal conditions and inducing mucosal immune responses.
Innovation Solution
Development of genetically modified Ad40-based vectors with reduced E1 coding region expression, allowing broader cell type compatibility and targeted delivery to the gastrointestinal tract, including the use of heterologous polynucleotides for therapeutic or prophylactic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If adenovirus-based vectors use standard replication mechanisms, then they can replicate efficiently in specific cell lines, but their application is limited to those specific cell lines and cannot effectively treat gastrointestinal conditions
Solution Approach 1:
The patent extracts the E1 coding region from the adenovirus genome, creating a replication-deficient vector that cannot replicate on its own. This extracted modification allows the vector to be applied across multiple cell types including gastrointestinal cells, while the heterologous polynucleotide provides the necessary functions for therapeutic effect without requiring broad replication capability
Solution Approach 2:
The modified adenovirus vector is designed to function universally across different cell types by incorporating heterologous polynucleotides that provide essential functions. The vector can transduce various cells including gastrointestinal epithelial cells, immune cells, and stromal cells, making it versatile for treating different conditions while maintaining controlled expression through specific promoters
2Adaptability or versatility
If adenovirus vectors are modified to decrease E1 expression for broader cell compatibility, then they can transduce multiple cell types including GI tract cells, but they lose the ability to replicate efficiently without specific cell lines
Solution Approach 1:
The E1 coding region is removed or deleted from the adenovirus vector, eliminating the requirement for specific cell line replication. This extraction enables the vector to transduce mucosal tissues and gastrointestinal cells effectively, while the heterologous polynucleotide compensates for the lost replication function through targeted therapeutic expression
Solution Approach 2:
The vector modifies key parameters including deleting E1 regions and incorporating heterologous polynucleotides with tissue-specific promoters. These parameter changes transform the vector from requiring strict cell line dependency to achieving broad mucosal tropism and targeted gene delivery across multiple tissue types
3Ease of manufacture
If the vector uses wild-type adenovirus structure, then it maintains natural replication properties, but it cannot effectively deliver therapeutic polynucleotides to gastrointestinal tissues
Solution Approach 1:
The adenovirus vector is segmented into functional modules: the backbone provides structural integrity and manufacturability, while separate heterologous polynucleotide insertions provide targeted therapeutic functions. This segmentation allows independent optimization of production simplicity and targeted delivery capability to gastrointestinal tissues
Solution Approach 2:
The vector applies local quality modifications by inserting heterologous polynucleotides with tissue-specific promoters and signaling sequences at specific locations. This enables targeted delivery to gastrointestinal epithelial cells, immune cells, and stromal cells while maintaining the overall vector structure for straightforward manufacturing
Data Source
AI summary
Ad40-based polynucleotides, viral vectors, methods of making such polynucleotides and viral vectors, pharmaceutical compositions that includes such polynucleotides and viral vectors, and uses of such compositions are disclosed herein. Generally, the Ad40-based polynucleotide includes an Ad40-based vector that includes a genetic modification that decreases expression of an E1 coding region and a heterologous polynucleotide.